TCR2 THERAPEUTICS INC. Quarterly Research and Development Expense in USD from Q1 2018 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
Summary
Tcr2 Therapeutics Inc. quarterly/annual Research and Development Expense history and growth rate from Q1 2018 to Q1 2023.
  • Tcr2 Therapeutics Inc. Research and Development Expense for the quarter ending March 31, 2023 was $29.3M, a 31.1% increase year-over-year.
  • Tcr2 Therapeutics Inc. Research and Development Expense for the twelve months ending March 31, 2023 was $106M, a 32% increase year-over-year.
  • Tcr2 Therapeutics Inc. annual Research and Development Expense for 2022 was $98.6M, a 34.1% increase from 2021.
  • Tcr2 Therapeutics Inc. annual Research and Development Expense for 2021 was $73.6M, a 41.6% increase from 2020.
  • Tcr2 Therapeutics Inc. annual Research and Development Expense for 2020 was $52M, a 38.7% increase from 2019.
Research and Development Expense, Trailing 12 Months (USD)
Research and Development Expense, Quarterly (USD)
Research and Development Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2023 $106M $29.3M +$6.95M +31.1% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-11
Q4 2022 $98.6M $25.8M +$7.02M +37.4% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-23
Q3 2022 $91.6M $24.8M +$4.51M +22.3% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-08
Q2 2022 $87.1M $25.8M +$7.14M +38.3% Apr 1, 2022 Jun 30, 2022 10-Q 2022-08-08
Q1 2022 $80M $22.3M +$6.4M +40.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $73.6M $18.8M +$4.45M +31.1% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-23
Q3 2021 $69.1M $20.3M +$7.46M +58.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $61.7M $18.6M +$5.72M +44.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $55.9M $15.9M +$3.97M +33.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $52M $14.3M +$4.91M +52.2% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-16
Q3 2020 $47.1M $12.8M +$1.45M +12.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $45.6M $12.9M +$4.07M +46.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $41.6M $12M +$4.07M +51.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 $37.5M $9.39M +$3.17M +51% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-16
Q3 2019 $34.3M $11.4M +$5.99M +111% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-16
Q2 2019 $28.3M $8.83M +$3.66M +70.7% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-16
Q1 2019 $24.7M $7.89M +$5M +173% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-16
Q4 2018 $19.7M $6.22M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-30
Q3 2018 $5.39M Jul 1, 2018 Sep 30, 2018 10-K 2020-03-30
Q2 2018 $5.18M Apr 1, 2018 Jun 30, 2018 10-K 2020-03-30
Q1 2018 $2.89M Jan 1, 2018 Mar 31, 2018 10-K 2020-03-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.